Chimerix Inc (CMRX) 41.78 $CMRX
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 91.26 (-0.46), TTPH: 39.72 (+0.01), AVNR: 16.94 (-0.01), SWKS: 73.32 (+0.61), CMRX: 41.78 (+1.52), ACHN: 13.33 (+1.08), HA: 25.27 (-0.78), RCPT: 124.81 (+2.30), PTCT: 51.00 (-0.77), AGIO: 109.76 (-2.28)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 26.48 (+0.36), INO: 9.32 (+0.14), JNJ: 104.52 (-0.05), BBC: 28.40 (+0.66), BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), MRK: 57.19 (+0.40), SRPT: 14.94 (+0.47), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37)
5 Best Performing Stocks of the Nasdaq in 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:58AM CST
The tech-laden Nasdaq Composite index enjoyed a bull run this year banking on broad based gains among Internet and bio-tech stocks, better-than expected GDP numbers and Fed's assurance about the economy.
CMRX: 41.78 (+1.52), SWKS: 73.32 (+0.61), IBM: 162.06 (+1.62), CHL: 58.49 (-0.33), HZNP: 12.80 (-0.09), TKMR: 14.76 (-0.39), GOOGL: 529.55 (-1.11), MSFT: 46.76 (+0.31), AAPL: 109.33 (-1.05), PLNR: 8.36 (-0.01), AVGO: 100.09 (-0.50), RFMD: 16.59 (-0.35)
Chimerix Provides Recap of 2014 Events
GlobeNewswire - Tue Dec 23, 7:37AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today provided a year-end recap of 2014 highlights for the investigational oral broad-spectrum antiviral brincidofovir.
CMRX: 41.78 (+1.52)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 342.01 (+2.56), VRX: 144.45 (+1.34), QLTI: 4.08 (+0.07), CTRX: 52.21 (+0.46), BCRX: 12.14 (-0.02), ACT: 259.13 (+1.72), MDT: 71.88 (-0.32), TKMR: 14.76 (-0.39), NEPT: 1.88 (-0.02), BSX: 13.22 (-0.03), AGN: 212.75 (+0.16), CMRX: 41.78 (+1.52), ALNY: 97.77 (+0.77), SRPT: 14.94 (+0.47), SHPG: 209.01 (-3.53), NLNK: 43.65 (+3.90), SNY: 45.52 (-0.09), MSLI: 1.63 (-0.02), NVCN: 6.50 (-0.32), CRME: 9.36 (+0.11), EBS: 26.90 (-0.33), GSK: 42.37 (-0.37), CELG: 113.52 (+1.66), GILD: 94.91 (+0.65), MRK: 57.19 (+0.40), NVDQ: 16.31 (-0.31), NVS: 92.25 (-0.41)
Chimerix and ContraVir team up in antiviral development
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 9:23AM CST
CMRX: 41.78 (+1.52), GILD: 94.91 (+0.65)
Chimerix appoints Ronald C. Renaud Jr to board
M2 - Thu Dec 18, 7:12AM CST
Biopharmaceutical company Chimerix (NasdaqGM:CMRX) revealed on Wednesday the addition of Ronald C. Renaud Jr to its board of directors.
CMRX: 41.78 (+1.52), PTCT: 51.00 (-0.77)
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
PR Newswire Europe - Thu Dec 18, 5:00AM CST
-- ContraVir to develop CMX157 for multiple antiviral indications --
SGYP: 3.20 (+0.15), CMRX: 41.78 (+1.52)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.62 (+0.04), PFNX: 7.50 (+0.32), INO: 9.32 (+0.14), CMRX: 41.78 (+1.52), RPTP: 10.40 (-0.12), IBIO: 0.65 (-0.03), ANAC: 31.74 (-0.51), PFE: 31.33 (+0.18), GNCA: 7.60 (+0.60), GSK: 42.37 (-0.37), AZN: 70.40 (+0.02), NVS: 92.25 (-0.41)
Chimerix Appoints Ronald C. Renaud, Jr. to Board of Directors
GlobeNewswire - Wed Dec 17, 3:30PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced Ronald C. Renaud, Jr. has been appointed to Chimerix's Board of Directors. Mr. Renaud currently serves as Chief Executive Officer at RaNA Therapeutics.
CMRX: 41.78 (+1.52)
BioCryst starts Phase 1 trial for hemorrhagic fever treatment
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:02AM CST
BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), HEB: 0.25 (unch), SRPT: 14.94 (+0.47), TKMR: 14.76 (-0.39), ABIO: 1.04 (+0.09)
Today's Dead Cat Bounce Stock: Chimerix (CMRX)
at The Street - Fri Dec 12, 8:54AM CST
Trade-Ideas LLC identified Chimerix (CMRX) as a "dead cat bounce" (down big yesterday but up big today) candidate
CMRX: 41.78 (+1.52)
Biotech industry group supports adding Ebola to Voucher Program Act
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 12:57PM CST
JNJ: 104.52 (-0.05), BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), HEB: 0.25 (unch), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37)
Chimerix to Present at the Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 7:07AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present at the Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 4:30pm EST at the New York Palace Hotel in New York.
CMRX: 41.78 (+1.52)
SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST
BCRX: 12.14 (-0.02), VSR: 3.13 (-0.03), TKMR: 14.76 (-0.39), NNVC: 2.70 (-0.02), INO: 9.32 (+0.14), CMRX: 41.78 (+1.52), APT: 2.61 (+0.04), HEB: 0.25 (unch), SRPT: 14.94 (+0.47), SMED: 4.41 (+0.15), PLX: 1.87 (+0.03), NLNK: 43.65 (+3.90), LAKE: 9.30 (-0.07), NSPH: 0.41 (+0.02)
Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:06AM CST
BCRX: 12.14 (-0.02), VSR: 3.13 (-0.03), TKMR: 14.76 (-0.39), NNVC: 2.70 (-0.02), INO: 9.32 (+0.14), CMRX: 41.78 (+1.52), APT: 2.61 (+0.04), HEB: 0.25 (unch), SRPT: 14.94 (+0.47), SMED: 4.41 (+0.15), NLNK: 43.65 (+3.90), PLX: 1.87 (+0.03), LAKE: 9.30 (-0.07), NSPH: 0.41 (+0.02)
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 39.72 (+0.01), JNJ: 104.52 (-0.05), BCRX: 12.14 (-0.02), NAVB: 1.93 (+0.04), CMRX: 41.78 (+1.52), SRPT: 14.94 (+0.47), NBS: 3.73 (-0.04), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37), CEMP: 22.89 (-0.62), OMER: 25.01 (+0.23)
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 91.26 (-0.46), TTPH: 39.72 (+0.01), AVNR: 16.94 (-0.01), SWKS: 73.32 (+0.61), CMRX: 41.78 (+1.52), ACHN: 13.33 (+1.08), HA: 25.27 (-0.78), RCPT: 124.81 (+2.30), PTCT: 51.00 (-0.77), AGIO: 109.76 (-2.28)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 26.48 (+0.36), INO: 9.32 (+0.14), JNJ: 104.52 (-0.05), BBC: 28.40 (+0.66), BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), MRK: 57.19 (+0.40), SRPT: 14.94 (+0.47), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37)
5 Best Performing Stocks of the Nasdaq in 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:58AM CST
The tech-laden Nasdaq Composite index enjoyed a bull run this year banking on broad based gains among Internet and bio-tech stocks, better-than expected GDP numbers and Fed's assurance about the economy.
CMRX: 41.78 (+1.52), SWKS: 73.32 (+0.61), IBM: 162.06 (+1.62), CHL: 58.49 (-0.33), HZNP: 12.80 (-0.09), TKMR: 14.76 (-0.39), GOOGL: 529.55 (-1.11), MSFT: 46.76 (+0.31), AAPL: 109.33 (-1.05), PLNR: 8.36 (-0.01), AVGO: 100.09 (-0.50), RFMD: 16.59 (-0.35)
Chimerix Provides Recap of 2014 Events
GlobeNewswire - Tue Dec 23, 7:37AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today provided a year-end recap of 2014 highlights for the investigational oral broad-spectrum antiviral brincidofovir.
CMRX: 41.78 (+1.52)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 342.01 (+2.56), VRX: 144.45 (+1.34), QLTI: 4.08 (+0.07), CTRX: 52.21 (+0.46), BCRX: 12.14 (-0.02), ACT: 259.13 (+1.72), MDT: 71.88 (-0.32), TKMR: 14.76 (-0.39), NEPT: 1.88 (-0.02), BSX: 13.22 (-0.03), AGN: 212.75 (+0.16), CMRX: 41.78 (+1.52), ALNY: 97.77 (+0.77), SRPT: 14.94 (+0.47), SHPG: 209.01 (-3.53), NLNK: 43.65 (+3.90), SNY: 45.52 (-0.09), MSLI: 1.63 (-0.02), NVCN: 6.50 (-0.32), CRME: 9.36 (+0.11), EBS: 26.90 (-0.33), GSK: 42.37 (-0.37), CELG: 113.52 (+1.66), GILD: 94.91 (+0.65), MRK: 57.19 (+0.40), NVDQ: 16.31 (-0.31), NVS: 92.25 (-0.41)
Chimerix and ContraVir team up in antiviral development
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 9:23AM CST
CMRX: 41.78 (+1.52), GILD: 94.91 (+0.65)
Chimerix appoints Ronald C. Renaud Jr to board
M2 - Thu Dec 18, 7:12AM CST
Biopharmaceutical company Chimerix (NasdaqGM:CMRX) revealed on Wednesday the addition of Ronald C. Renaud Jr to its board of directors.
CMRX: 41.78 (+1.52), PTCT: 51.00 (-0.77)
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
PR Newswire Europe - Thu Dec 18, 5:00AM CST
-- ContraVir to develop CMX157 for multiple antiviral indications --
SGYP: 3.20 (+0.15), CMRX: 41.78 (+1.52)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.62 (+0.04), PFNX: 7.50 (+0.32), INO: 9.32 (+0.14), CMRX: 41.78 (+1.52), RPTP: 10.40 (-0.12), IBIO: 0.65 (-0.03), ANAC: 31.74 (-0.51), PFE: 31.33 (+0.18), GNCA: 7.60 (+0.60), GSK: 42.37 (-0.37), AZN: 70.40 (+0.02), NVS: 92.25 (-0.41)
Chimerix Appoints Ronald C. Renaud, Jr. to Board of Directors
GlobeNewswire - Wed Dec 17, 3:30PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced Ronald C. Renaud, Jr. has been appointed to Chimerix's Board of Directors. Mr. Renaud currently serves as Chief Executive Officer at RaNA Therapeutics.
CMRX: 41.78 (+1.52)
BioCryst starts Phase 1 trial for hemorrhagic fever treatment
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:02AM CST
BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), HEB: 0.25 (unch), SRPT: 14.94 (+0.47), TKMR: 14.76 (-0.39), ABIO: 1.04 (+0.09)
Today's Dead Cat Bounce Stock: Chimerix (CMRX)
at The Street - Fri Dec 12, 8:54AM CST
Trade-Ideas LLC identified Chimerix (CMRX) as a "dead cat bounce" (down big yesterday but up big today) candidate
CMRX: 41.78 (+1.52)
Biotech industry group supports adding Ebola to Voucher Program Act
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 12:57PM CST
JNJ: 104.52 (-0.05), BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), HEB: 0.25 (unch), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37)
Chimerix to Present at the Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 7:07AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present at the Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 4:30pm EST at the New York Palace Hotel in New York.
CMRX: 41.78 (+1.52)
SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST
BCRX: 12.14 (-0.02), VSR: 3.13 (-0.03), TKMR: 14.76 (-0.39), NNVC: 2.70 (-0.02), INO: 9.32 (+0.14), CMRX: 41.78 (+1.52), APT: 2.61 (+0.04), HEB: 0.25 (unch), SRPT: 14.94 (+0.47), SMED: 4.41 (+0.15), PLX: 1.87 (+0.03), NLNK: 43.65 (+3.90), LAKE: 9.30 (-0.07), NSPH: 0.41 (+0.02)
Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:06AM CST
BCRX: 12.14 (-0.02), VSR: 3.13 (-0.03), TKMR: 14.76 (-0.39), NNVC: 2.70 (-0.02), INO: 9.32 (+0.14), CMRX: 41.78 (+1.52), APT: 2.61 (+0.04), HEB: 0.25 (unch), SRPT: 14.94 (+0.47), SMED: 4.41 (+0.15), NLNK: 43.65 (+3.90), PLX: 1.87 (+0.03), LAKE: 9.30 (-0.07), NSPH: 0.41 (+0.02)
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 39.72 (+0.01), JNJ: 104.52 (-0.05), BCRX: 12.14 (-0.02), NAVB: 1.93 (+0.04), CMRX: 41.78 (+1.52), SRPT: 14.94 (+0.47), NBS: 3.73 (-0.04), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37), CEMP: 22.89 (-0.62), OMER: 25.01 (+0.23)
